Once-daily antipsychotic gets nod for schizophrenia

May 28, 2007

The atypical antipsychotic quetiapine fumarate is now available in an extended-release formulation. Seroquel XR, from AstraZeneca, has been approved by the FDA for the treatment of schizophrenia in adults.

The atypical antipsychotic quetiapine fumarate is now available in an extended-release formulation. Seroquel XR, from AstraZeneca, has been approved by the FDA for the treatment of schizophrenia in adults following evaluation of clinical trial data in a study of 573 patients experiencing acute exacerbation of symptoms of schizophrenia. Following six weeks of treatment, patients taking 400, 600, and 800 mg per day of quetiapine extended-release showed a significant improvement in Positive and Negative Syndrome Scale (PANSS) total scores compared with placebo. According to the manufacturer, Seroquel XR will be produced as 200-, 300-, and 400-mg strength tablets and will be available in the U.S. market by the end of July.

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.